Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective

European Journal of Cancer Part A

Volumn 32, Issue SUPPL. 3, 1996, Pages

  Bleiberg, H ^a   Cvitkovic, E ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

cancer; chemotherapy; colorectal; CPT 11; diarrhoea; toxicity

Indexed keywords

ACETORPHAN; IRINOTECAN; LOPERAMIDE; UNCLASSIFIED DRUG;

ALOPECIA; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0029964873     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00293-6     Document Type: Article

References (11)

1. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
2. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995, 13, 1303-1311.
3. Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989, 7, 1419-1426.
4. Advanced Colorectal Cancer Meta-Analysis Project. Meta analysis of randomised trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994, 12, 960-969.
5. Kemeny N, Younes A, Seiter K, et al. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Cancer 1990, 66, 2470-2475.
6. Armand JP, Ducreux M, Mahjoubi H, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995, 31A, 1283-1287.
7. Abigerges D, Chabot GG, Armand J, et al. Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995, 13, 210-221.
8. Catimel G, Chabot GG, Guastalla JP, et al. Phase I and pharmacokinetic study of irinotecan (CPT 11) administered daily for three consecutive days every three weeks in patients with advanced solid tumours. Ann Oncol 1995, 6, 133-140.
9. De Forni M, Bugat R, Chabot GG, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994, 54, 4347-4354.
10. Rougier P, Culine S, Bugat R, et al. A phase II study of CPT-11 (irinotecan) in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with 5-FU-based chemotherapy. J Clin Oncol 1996, in press.
11. Cascinu S. Drug therapy in diarrheal diseases in oncology hematology patients. Crit Rev Oncol/Hematol 1995, 18, 37-50.